How does NanoKnife work for prostate cancer?

Prostate cancer treatment is often a balance between controlling the cancer and preserving everyday function. When disease is confined to one area of the gland, many patients ask a reasonable question: does the whole prostate really need to be treated?

NanoKnife — the brand name for irreversible electroporation (IRE) — is one answer to that question. It is a focal therapy, meaning it targets the cancer-affected part of the prostate rather than the whole gland. That makes it an appealing option for carefully selected men with localised prostate cancer, though it is not a routine first-line treatment in every setting, and NICE treats it as a selected-use procedure requiring special governance arrangements.

How NanoKnife and IRE work — the mechanism

The mechanism of NanoKnife is fundamentally different from surgery, HIFU, cryotherapy, and radiotherapy. It does not cut, heat, freeze, or irradiate the target tissue. Instead, it uses controlled electrical pulses to kill cancer cells by disrupting their cell membranes.

During treatment, thin electrodes are placed into and around the target area within the prostate under imaging guidance. Short bursts of high-voltage, low-energy electrical current are then delivered between those electrodes in a precisely calibrated sequence. The electrical field created between the electrodes affects the membranes of the cells within the treatment zone.

The pulses create tiny permanent openings — often described as nanopores — in the cell membranes of the targeted tissue. When enough nanopores accumulate, the cells can no longer maintain their internal environment. Normal homeostatic mechanisms fail, and the cells die. This process is called irreversible electroporation, which is where the clinical name comes from.

Why the non-thermal mechanism matters

The fact that IRE does not rely on heat or cold is clinically significant. Thermal ablation methods — HIFU, cryotherapy, and radiofrequency ablation — all carry a risk of thermal spread: heat or cold may propagate beyond the intended treatment zone and potentially affect adjacent structures. The urethra, neurovascular bundles, and rectum all sit close to the prostate.

IRE's non-thermal mechanism means the electrical field acts on cell membranes without generating significant heat in the surrounding tissue. Connective tissue scaffolding — including the structural framework of blood vessels and nerves — is thought to be largely preserved within the treatment zone, even as the cells within it are destroyed. This is one of the theoretical advantages that has driven interest in IRE for tumours located close to the neurovascular bundles or the urethra, where thermal methods carry higher risk.

That said, "non-thermal" does not mean "no risk to adjacent structures." Electrode placement, pulse calibration, and prostate anatomy all influence what the treatment field actually affects. The non-thermal claim is a mechanistic property of the technique — not a guarantee of functional preservation in every case.

What happens during NanoKnife treatment for prostate cancer

Before any treatment decision, the cancer must be mapped as accurately as possible. Focal therapy only works when the target is well defined — and for NanoKnife, that means high-quality multiparametric MRI, targeted transperineal biopsy results, and careful review of where the cancer sits within the gland relative to critical structures.

Who is a realistic candidate for NanoKnife

IRE is considered for men with clinically localised prostate cancer where imaging and biopsy together suggest the disease is genuinely confined to a defined area of the gland. The key criteria that support a discussion about NanoKnife are broadly similar to those for other focal therapies, with some important practical differences.

Selection also involves broader clinical judgment. A patient's age, general health, existing urinary function, prior pelvic treatment, and personal values around the trade-off between certainty of cancer control and functional preservation all legitimately shape the recommendation. A man who wants the strongest possible long-term cancer control assurance is likely better served by robotic radical prostatectomy. A man with intermediate-risk unilateral disease who places high priority on functional preservation and is prepared for close follow-up may find IRE well matched to his situation.

Benefits and trade-offs — the honest picture

What NICE says about NanoKnife/IRE for prostate cancer

In the UK, NICE has stated that irreversible electroporation for prostate cancer should be used with special arrangements for clinical governance, patient consent, and audit or research. In plain terms, it is recognised as a treatment within the prostate cancer landscape, but not as a routine standard option for all patients.

That NICE position reflects the current evidence landscape honestly. There is growing clinical experience, improving technical quality, and encouraging outcomes data from specialist centres. Long-term comparative data — the kind that would allow a clear head-to-head comparison with surgery or radiotherapy over ten or fifteen years — are still being built.

For patients, the NICE position should not be read as a negative verdict. It means NanoKnife/IRE is best considered in a setting with high-quality imaging infrastructure, experienced operators, transparent consent, and a follow-up plan that is taken seriously — exactly the conditions in which focal therapy produces its best results.

Follow-up after NanoKnife — why it cannot be treated as optional

Because part of the prostate remains in place after IRE, the surveillance plan after treatment is as important as the treatment itself. PSA does not fall to undetectable levels after focal therapy — the untreated tissue continues to produce it. That makes follow-up more nuanced than after radical prostatectomy, and more demanding than some patients initially expect.

A standard follow-up protocol after NanoKnife typically includes PSA measurement at 3, 6, and 12 months, then six-monthly thereafter; multiparametric MRI at 6–12 months to assess the ablation zone and the preserved gland; and targeted transperineal biopsy at 12–18 months — even in the absence of PSA rise or imaging concern. Further biopsy is indicated if PSA trends suggest recurrence or if MRI identifies new suspicious areas.

Men who genuinely cannot commit to this surveillance schedule are not well suited to focal therapy, regardless of how appealing the treatment sounds. The follow-up is not an afterthought — it is built into what focal therapy is designed to do.